MINNEAPOLIS--(BUSINESS WIRE)--Jun. 18, 2014--
Jaffray (NYSE:PJC), a leading investment bank and asset management
firm, today announced that Chris Collins has joined the firm as a
principal in its biotechnology investment banking group. His experience
includes more than 14 years in financial services including 12 years
focused on the biotechnology industry. He will be based in the firm’s
San Francisco office.
“Our market-leading healthcare platform provides strategic advice and
capital raising capabilities in one of the most transformative and
important industries in the global economy,” commented Chad
Abraham, global co-head of investment banking and capital markets.
“We see a tremendous opportunity in the biotechnology sector and Chris
is an instrumental addition to our growing coverage team.”
Collins joins the firm from Citigroup, where he was a director in the
healthcare investment banking group focused on biotechnology companies.
He previously worked at Credit Suisse, CPC Capital Management, Frazier
Healthcare Ventures and Morgan Stanley.
Collins has represented biotechnology clients in transactions with an
aggregate transaction value exceeding $24 billion, including over $13
billion of mergers and acquisitions and over $11 billion of capital
markets transactions. He holds a bachelor’s degree in economics from
Stanford University and a master’s degree in biotechnology from Johns
Hopkins University. He is also a CFA® charterholder.
“We’ve focused on strategically growing our biotech investment banking
franchise for several years and have made significant headway in market
share gains and revenue growth. We are very pleased to add Chris to our
team. His unique background and industry relationships make him a highly
valuable advisor to our clients and our platform,” said Bob
DeSutter, head of Piper Jaffray healthcare investment banking.
Collins added, “Piper Jaffray has a longstanding reputation as the
investment bank of choice for healthcare companies. I look forward to
being part of one of the most respected and established teams in the
Piper Jaffray has a global healthcare
investment banking and capital
markets team of more than 50 professionals. Since 2007, the team has
represented clients in 318 transactions with an aggregate value of $54
billion. In addition, the firm’s 10
healthcare senior research analysts cover a broad spectrum of
sectors, including biotechnology, medical technology, specialty
pharmaceuticals, drug discovery, medical diagnostics, life science tools
and healthcare services, including information technology and alternate
About Piper Jaffray
Jaffray Companies (NYSE: PJC) is an investment bank and asset
management firm headquartered in Minneapolis with offices across the
U.S. and in London, Hong Kong* and Zurich. Securities brokerage and
investment banking services are offered in the United States through
Piper Jaffray & Co., member NYSE and SIPC, and in Europe through Piper
Jaffray Ltd., authorized and regulated by the Financial Conduct
Authority. Asset management products and services are offered through
three separate investment advisory affiliates registered with the U.S.
Securities and Exchange Commission: Advisory Research Inc., Piper
Jaffray Investment Management LLC and PJC Capital Partners LLC.
The CFA® is a registered trademark owned by CFA Institute.
Follow Piper Jaffray: LinkedIn
© 2014 Piper Jaffray Companies, 800 Nicollet Mall, Suite 1000,
Minneapolis, Minnesota 55402-7020
Source: Piper Jaffray Companies
Piper Jaffray Companies
Pamela Steensland, 612-303-8185